IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)
10-Q - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
PRE 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)
D - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
424B5 - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
424B3 - bioAffinity Technologies, Inc. (0001712762) (Filer)
Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024 Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024. Key Highlights Generated quarterly revenue of $2.4 million in the third quarter of 2024. More than 1,300% growth ra
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Certificate of Grant of Patent to bioAffinity Technologies for the method of predicting the likelihood of lung cancer used by the CyPath® Lung diagnostic test for early-stage lung cancer. The Japanese patent, titled "System and Method for Determining the State of Health of the Lungs," is an important addition to bioAffinity Technologies' patent portfolio, which includes 17 awarded U.S. and foreign patents and 30 pending patent applications relate
JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent private placement of common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share f
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent private placement of common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company. The Warrants are initially ex
JERSEY CITY, N.J., Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share. The Warrants are initially exercisable on the date that the Company's stockholders approve the exercise of the Warrants and the i
bioAffinity VP served on expert panel that published new guidance bioAffinity Technologies' (NASDAQ:BIAF, BIAFW))) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the peer-reviewed paper, "Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain," in the journal Cytometry Part B: Clinical Cytometry, the official journal of the International Clinical Cytometry Society. "Our CyPath® Lung noninvasive test for the early detection of lung cancer is a novel test that uses sputum, a unique sample type that is not typically used in clin
Edwards rejoins the Company after serving as interim CFO bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael Edwards has accepted the position of Chief Financial Officer (CFO). Edwards has been bioAffinity's interim CFO since Sept. 15 and previously served as bioAffinity's consulting CFO from 2014 to 2023, overseeing the Company's initial public offering (IPO) in 2022. Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes. "We are delighted to welcome Michael back to our executive leadership team. He was key to our
Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that CyPath® Lung, its noninvasive test to detect early-stage lung cancer, will be added to the U.S. Federal Supply Schedule, a procurement system that provides the Veterans Health Administration (VHA) and the Military Health System streamlined access to state-of-the-art healthcare products and services. The VHA, part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million Veterans each year a
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloombe
Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity's Board of Directors Conference Call at 4:30 p.m. Eastern time Today bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. The laboratory assets are being acquire
Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions. Event: bioAffinity Technologies Fourth Quarter 2022 Financial Results Date: Monday, April 3, 2023 Time: 9:00 a.m. EDT Toll Free: 1-877-270-2148 International: 1-412-902-6510 Webcast: Webcast link A replay o
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath® Lung, the Company's noninvasive test to detect early-stage lung cancer. Reported accelerating growth of 350% in CyPath® Lung tests ordered and processed in Q1 2024 as
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets. "Dr. Platt's impressive track record in transforming research organizations into successful commercial entities, her commitment to operational excellence and innovation, and her extensive experience in expanding product market share in the diagnostics market make her a valuable asset to our team as we move forward
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership with the American Cancer Society (ACS) to increase lung cancer screening in Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231115775728/en/A partnership to improve lung cancer screening. (Graphic: Business Wire) "The Power of Three" campaign emphasizes the importance of joining forces in the fight against lung cancer by supporting local programs like the Quality Improvement Program to Increase Lu
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America's therapeutic solutions division. Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. "We are delighted
Company enlists Havas Health & You, Trinity Life Sciences to help build CyPath® Lung brand bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies' Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector. CyPath® Lung is a non-invasive test that detects early-stage lung cancer by automated flow cytometry and machine learnin
Maxim Group analyst Anthony Vendetti initiates coverage on bioAffinity Technologies (NASDAQ:BIAF) with a Buy rating and announces Price Target of $6.
Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practicesbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today raised its full-year forecast for sales of CyPath® Lung in the Company's test marketing program by 85% and reported 217% growth in second-quarter sales over first quarter 2024, outpacing the forecast previously reported in May by 75%.CyPath® Lung fulfills the need for a noninvasive test for the early detection of lung cancer and is especially useful for patients whose lung cancer screening or other scan reveals a pulm
Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecastsbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath® Lung to patients since Jan. 1, 2024. CyPath® Lung is a noninvasive test to detect early-stage lung cancer.
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.21) per share. This is a 16.67 percent decrease over losses of $(0.18) per share from the same period last year. The company reported $2.41 million in sales this quarter. This is a 261.18K percent increase over sales of $921.00 the same period last year.
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) shares recent Company news.CyPath® Lung Sales Ramp Up Month over MonthSales of CyPath® Lung, our noninvasive diagnostic test for the early detection of lung cancer, continue to climb, with April sales up 21% over March. Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology Laboratory Services, to order CyPath® Lung for their patients. In addition to Texas, pulmonologists in New Jersey, Pennsylvania, Michigan and North Carolina have ordered CyPath® Lung diagnostic tests for their patients with pulmonary nodules.CyPath® Lung Sales, Support Teams Continue to GrowbioAffinity Technologies' Nation
Gainers Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutics (NASDAQ:GALT) shares increased by 20.66% to $3.62. The company's market cap stands at $224.0 million. Ocugen (NASDAQ:OCGN) stock moved upwards by 17.88% to $1.78. The company's market cap stands at $456.7 million. As per the press release, Q4 earnings came out 3 days ago. Processa Pharma (NASDAQ:PCSA) shares moved upwards by 17.67% to $2.73. The market value of their outstanding shares is at $4.6 million. bioAffinity Technologies (NASDAQ:BIAF) stock rose 15.5% to $2.98. The market value of their outstanding
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.26) per share. This is a 40.91 percent increase over losses of $(0.44) per share from the same period last year. The company reported $2.21 million in sales this quarter. This is a 5.67 percent decrease over sales of $2.35 million the same period last year.
Shares of Mesoblast Limited (NASDAQ:MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Kidpik Corp. (NASDAQ:PIK) gained 238% to $9.15. Kidpik recently announced a 1-for 5 reverse stock split. TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares surged 149% to $2.6450. TRxADE HEALTH, Inc. (NASDAQ:MEDS) gained 114.6% to $17.26. TRxADE Health recently announced a special cash dividend of $8 per share. Fangdd Network Group Ltd. (NASDAQ:DUO) shares
Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 76.41% to $1.87. The company's market cap stands at $4.5 million. bioAffinity Technologies (NASDAQ:BIAF) shares moved upwards by 28.1% to $1.96. The company's market cap stands at $21.8 million. Graphite Bio (NASDAQ:GRPH) stock moved upwards by 25.47% to $3.94. The market value of their outstanding shares is at $229.4 million. ASLAN Pharma (NASDAQ:ASLN) shares rose 24.8% to $0.78. The company's market cap stands at $13.0 million. Mesoblast (NASDAQ:MESO) stock rose 22.79% to $2.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.20% to 38,662.69 while the NASDAQ rose 0.64% to 16,041.08. The S&P 500 also rose, gaining, 0.53% to 5,105.72. Check This Out: Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday Leading and Lagging Sectors Information technology shares jumped by 1.1% on Wednesday. In trading on Wednesday, consumer discretionary shares fell 0.3%. Top Headline Campbell Soup Company (NYSE:CPB) reported better-than-expected earnings for its second quarter. The company posted a second-quarter FY24 decline of 1.2% year-